Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action

IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Lancet Microbe Pub Date : 2024-10-01 DOI:10.1016/S2666-5247(24)00109-5
{"title":"Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action","authors":"","doi":"10.1016/S2666-5247(24)00109-5","DOIUrl":null,"url":null,"abstract":"<div><div>In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive—ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"5 10","pages":"Article 100886"},"PeriodicalIF":20.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666524724001095","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive—ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
实施欧盟抗菌药创新和获取拉动激励机制:行动蓝图
2023 年 6 月,欧盟理事会公布了一项建议,即欧盟委员会应参与欧盟跨国拉动激励机制的设计和管理,以刺激抗菌药物的创新和获取。在这篇个人观点中,我们将讨论支持实施新的拉动式激励措施的六个关键考虑因素,即潜在拉动式激励措施的规模和成员国可能的贡献、激励模式的设计、新的拉动式激励措施与欧盟药品立法修订建议的相互作用、欧盟和成员国的角色和责任、拉动式激励措施和推动式激励措施之间的平衡以及全球合作和责任。由于成员国对欧盟拉动激励机制的参与将是自愿的,因此成员国应相信用于确定合格抗菌药物、谈判条款和条件以及监督准入协议的程序是透明的、包容的,并且在方法上是稳健的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Microbe
Lancet Microbe Multiple-
CiteScore
27.20
自引率
0.80%
发文量
278
审稿时长
6 weeks
期刊介绍: The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.
期刊最新文献
Genomic reconstruction of an azole-resistant Candida parapsilosis outbreak and the creation of a multi-locus sequence typing scheme: a retrospective observational and genomic epidemiology study. Reassessing the role of butyrate-producing bacteria in infection risk. Using demographics of patients to inform treatment of shigellosis in England. Variability of Mycobacterium tuberculosis lipid body content in sputum and its implications for treatment response. Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1